Natural killer (NK) cells are known to be a critical part of the immune system involved in tumor control. In human and animal models, NK cell deficiency leads to increased incidence of different types of tumors ([@r1]). While the role of NK cells in tumor immune surveillance is well established and experimentally supported ([@r2]), the use of NK cells is far from being successfully and fully used in the clinic, although efforts are now being undertaken to exploit their antitumor properties ([@r3]). This might be in part related to the lack of crucial knowledge about NK cell-homing capacities ([@r4], [@r5]) and their poor infiltration into solid tumors ([@r6]). Indeed, the long-lasting observations showing that NK cells are infrequently detected in tumor biopsies suggest that intratumoral NK cells can be associated with increased survival of cancer patients ([@r7]). Therefore, strategies aiming at increasing the infiltration of NK cells into tumors would be of great interest to improve NK-based tumor immunotherapies ([@r8]). Consequently, a deeper understanding of the mechanisms regulating NK cell infiltration will allow us to take full advantage of the tremendous antitumor capacities of NK cells and rapidly bring them to the clinical use.

In this regard, it should be emphasized that the infiltration of functional cytotoxic immune cells, including NK and cytotoxic T lymphocytes (CTLs), will likely become a major factor in achieving successful immunotherapies, notably those based on the use of immune checkpoint inhibitors. Accumulating new evidence highlights that, similar to CTLs, activated NK cells can express, under some circumstances, the immune checkpoint programmed cell death protein 1- (PD-1) ([@r9][@r10]--[@r11]) and CTL-associated antigen 4 (CTLA4) ([@r12]). Thus, it stands to reason that improving the infiltration of cytotoxic immune cells, including NKs, into the tumor bed could enhance the therapeutic benefit of NK cell-based immunotherapy and provide novel therapeutic targets that could complement the expanding armamentarium of cancer immunotherapies.

Chemokines are chemotactic cytokines playing a major role in the infiltration of immune cells into the tumor bed, and are therefore supposed to play a tumor-suppressive role ([@r13]). However, depending on the balance between several tumor-promoting and tumor-inhibiting factors, some cytokines may play a dual role in tumor promotion or tumor suppression. For example, several cytokines expressed by melanomas are involved in tumor growth and progression, including CXCL1, CXCL2, CXCL3, CXCL8, CCL2, and CCL5 ([@r14]). In contrast, it has been shown that chemotherapy can also induce the expression of cytokines, including CCL5, involved in the trafficking of T cells into the tumor bed ([@r15]). Therefore, a positive correlation between the expression of some cytokines and the clinical outcome has been proposed ([@r16]). It is now well defined that the dual role played by some cytokines as tumor-promoting or tumor-suppressing depends on the balance between tumor-promoting and tumor-inhibiting factors. Therefore, understanding the complex role of chemokines in tumor biology and the context by which they play such a dual role will contribute to the improvement of the efficacy of cancer immunotherapeutic strategies and the induction of long-lasting host antitumor immunity.

Using syngeneic melanoma and breast mouse models, we have previously reported that targeting the autophagy gene Beclin1 (*BECN1*) significantly inhibited tumor growth by improving NK-mediated antitumor immune response ([@r17]). Briefly, autophagy is a lysosomal degradation pathway executed at the basal level that allows cells to self-digest their own components and rid themselves of damaged organelles and misfolded proteins in well-defined structures, named autophagosomes. Such a degradation process provides nutrients to maintain cellular functions under environmental stresses, thus allowing survival of cancer cells under stress conditions ([@r18], [@r19]). Autophagy involves a BECN1/class III phosphoinositide-3-kinase (PI3K) complex to initiate the formation of an isolation membrane, called the phagophore ([@r20]). *ATG5*, another autophagy-related protein, plays a role in the elongation of the phagophore and in its subsequent maturation into the complete autophagosome ([@r21]). Consistent with the degradation property of autophagy, we have demonstrated that targeting *BECN1* prevented the degradation of NK-derived GranzymeB (GzmB) in hypoxic melanoma cells, and therefore restored their susceptibility to NK cell-mediated killing ([@r17]). A growing body of evidence suggests that autophagy could operate in tumor cells as an immunosuppressive and cell-resistance mechanism, because autophagy blockade not only sensitizes tumor to chemotherapy ([@r22]) but also improves the antitumor immune response ([@r23], [@r24]).

In this study, we investigated the impact of targeting autophagy on the infiltration of NK cells into the tumor bed. We show that targeting *BECN1* in melanoma tumor induced a massive infiltration of functional NK cells into the tumor by a mechanism involving the secretion of high levels of CCL5, since the infiltration was no longer observed after silencing *CCL5*. In autophagy-defective tumor cells, we provide evidence that the induction of CCL5 is transcriptionally related to the increase in the phosphorylation of c-Jun at Ser-63 and -73. We also provide clinical evidence supporting our data by showing a positive correlation between the expression of CCL5 and the NK cell marker NKp46 in melanoma patients. In addition, high expression of *CCL5* was correlated with an overall improved survival of melanoma patients.

Results {#s1}
=======

Targeting Autophagy Related Gene *BECN1* Improves the Recruitment of Functional NK Cells into the Tumor Bed. {#s2}
------------------------------------------------------------------------------------------------------------

We have previously reported that targeting *BECN1* significantly reduces the growth of B16-F10 mouse tumors. This effect is primarily related to the improvement of NK-mediated tumor cell killing, as such reduction was no longer observed in NK cell-depleted mice ([@r17]). Although NK cells seem to play a major role in the control of B16-F10 tumor growth, it should be emphasized that the reduced BECN1-defective (BECN1^−^) B16-F10 tumor volume was also rescued, but to a lesser extent, by the depletion of CD8 T cells. In this study, we investigated whether targeting *BECN1* inhibits the tumor growth by improving the infiltration of NK cells into the tumor bed. Immunohistochemistry staining of tumor sections revealed a massive infiltration of NK cells into *BECN1*^−^ compared with control (Ctrl) tumors ([Fig. 1*A*](#fig01){ref-type="fig"}).

![BECN1^−^ B16-F10 tumors contain higher numbers of active NK cells compared with Ctrl tumors. (*A*) Immunohistochemical staining of NK cells performed on control (Ctrl) or BECN1^−^ B16-F10 tumor sections using anti--Asialo-GM1. (Scale bar, 200 µm.) (*B*) Tumor-infiltrating NK cells were stained with NK1.1, CD69-, and GzmB-specific antibodies. Total NK cells (CD45^+^NK1.1^+^) were gated and the percentage of active NK cells (NK1.1^+^CD69^+^ and NK1.1^+^GzmB^+^) was determined by multicolor flow cytometry. Images represent flow cytometric plots of CD45^+^NK1.1^+^, NK1.1^+^CD69^+^, and NK1.1^+^GzmB^+^ cells infiltrating Ctrl and BECN1^−^ B16-F10 tumors. (*C*) Quantification of total NK1.1^+^ and active (NK1.1^+^CD69^+^ and NK1.1^+^GzmB^+^) NK cells infiltrating Ctrl and BECN1- B16-F10 tumors, reported as a percentage (%). (*D*) Quantification of CD69^+^/NK1.1^+^ (*Left*) and GzmB^+^/NK1.1^+^ (*Right*) cells infiltrating control Ctrl and BECN1^−^ B16-F10 tumors, reported as a percentage (%). Results are the average ± SEM of three mice from each group. \**P* \< 0.05; \*\**P* \< 0.01; ns, not significant (two-tailed Student's *t* test).](pnas.1703921114fig01){#fig01}

Since NK cell-infiltrating tumors could be functionally impaired/exhausted ([@r25]), we then assessed the functional properties of the NK cells that infiltrated BECN1^−^ tumors. Flow cytometry analysis, performed based on the gating strategy described in [Fig. S1](#sfig01){ref-type="fig"}, on Ctrl and BECN1^−^ B16-F10 tumors confirmed our results obtained by immunohistochemistry result and revealed an almost twofold increase in the number of NK cell-infiltrating BECN1^−^ tumors compared with Ctrl ([Fig. 1 *B* and *C*](#fig01){ref-type="fig"}). Furthermore, our data show that infiltrated NK cells were CD69^+^ and GzmB^+^, indicating that they were fully functional in the BECN1^−^ tumor bed ([Fig. 1 *B* and *C*](#fig01){ref-type="fig"}). Interestingly, when reported to the total number of NK cells, no difference in the activation status of NK cells infiltrating both Ctrl and BECN1^−^ tumors was found ([Fig. 1*D*](#fig01){ref-type="fig"}). This result shows that targeting *BECN1* increases the number of infiltrated NK cells without affecting their activation properties. Together, our data highlight that targeting *BECN1* presumably inhibits the growth of B16-F10 tumors at least in part by improving the homing of functional NK cells into the tumor bed.

![Gating strategy and flow cytometric analysis. (*A*) Data represent dot plots demonstrating the gating and analytical processes for NK1.1, CD69, and GzmB staining of CD45^+^CD11b^−^CD19^−^ cells from B16-F10 tumors. Cell suspensions harvested from tumors were stained with BV421--anti-NK1.1, Al700--anti-CD19, APC-R700--anti-CD11b, BUV395--anti-CD45, BV605--anti-CD69, Pacific blue anti-GzmB, and near IR-live/dead. Cells were first gated for forward scatter-A (FSC-A) vs. side scatter-A (SSC-A), and then for cell singlets forward scatter-A (FSC-A) vs. forward scatter-W (FSC-W). Live cells were gated and the gate encompassing CD45^+^CD11b^−^CD19^−^ cells were analyzed for the expression of NK1.1, GzmB, and CD69. The quadrants were defined based on the cells stained with fluorescence-minus-one (FMO) and then applied to the plots of cells stained with positive antibodies, as shown in [Fig. 1*A*](#fig01){ref-type="fig"}. (*B*) Data represent dot plots demonstrating the gating and analytical processes for CCR1, CCR3, and CCR5 staining of NK1.1^+^ and tumor (CD45^−^) cells gated as described in *A*. The gates encompassing for NK1.1^+^ and CD45^−^ cells were analyzed for their expression of CCR1, CCR3, and CCR5. The quadrants were defined based on the cells stained with FMO and then applied to the plots of cells stained with positive antibodies, as shown in [Figs. S3](#sfig03){ref-type="fig"} and [S4](#sfig04){ref-type="fig"}.](pnas.1703921114sfig01){#sfig01}

Targeting Autophagy Induces the Expression of CCL5, Which Is Involved in the Migration of NK Cells. {#s3}
---------------------------------------------------------------------------------------------------

It is well established that tumors displaying high number of cytotoxic immune cells secrete high amounts of attracting chemokines ([@r26], [@r27]). Consequently, we evaluated whether the improvement of the infiltration of NK cells into BECN1^−^ B16-F10 tumors is related to the regulation of some chemokines involved in the migration of NK cells. A cytokine profiling assay, performed using the conditioned medium of tumor cells, revealed that targeting *BECN1* increased the secretion of several chemokines, including CCL5, CXCL10, and TIMP1 ([Fig. 2*A*](#fig02){ref-type="fig"}, *Left*). The quantification of the results obtained by cytokine arrays revealed that CCL5 was the predominant up-regulated cytokine in BECN1^−^ tumor cells compared with CXCL10 or TIMP1 ([Fig. 2*A*](#fig02){ref-type="fig"}, *Right*). Based on these data, we focused our interest on CCL5 and quantified its level in the conditioned media of Ctrl and BECN1^−^ B16-F10 tumor cells by ELISA. [Fig. 2*B*](#fig02){ref-type="fig"} shows that BECN1^−^ cells secreted 4.5-fold more CCL5 compared with Ctrl cells (525 and 112 pg/mL for BECN1^−^ and Ctrl, respectively).

![BECN1^−^ melanoma cells secrete high level of CCL5. (*A*, *Left*) Identification of cytokines in the supernatants of Ctrl (up) and BECN1^−^ (down) B16-F10 cells using a Mouse Cytokine Array. Highly expressed cytokines (CCL5, TIMP1, and CXCL10) regulated in BECN1^−^ cells are highlighted in red. (*Right*) Quantification of CCL5, TIMP1, and CXCL10 spots of the *Left* panel reported as fold-change compared with the Ctrl. (*B*) Quantification of CCL5 in the supernatant of Ctrl and BECN1^−^ B16-F10 cells by ELISA. Results are the average ± SEM of three independent experiments. \**P* \< 0.05 (two-tailed Student's *t* test). (*C*) Expression of CCL5 in A375, IPC298, and MelJuso human melanoma cell lines. (*Upper*) Quantification of CCL5 secretion by ELISA in the supernatants of the indicated human melanoma cells transfected with either control (Ctrl) or *BECN1* siRNA (BECN1^−^). Data represent the average ± SEM of four (*Left* and *Right*) or three (*Center*) independent experiments. \**P* \< 0.05; \*\*\**P* \< 0.001 (two-tailed Student's *t* test). (*Lower*) Expression of Beclin1 protein was assessed by Western blot. Actin was used as loading control. (*D*) Migration of NK92MI cell line toward recombinant CCL5 gradient. Migration of NK cells toward serum-free medium in the absence (*Left*) or presence of 20 ng/mL of recombinant CCL5 (*Right*). Red and black points represent NK cells migrating to the top and bottom compartments, respectively. The percentage of migrating NK cells are reported in the bottom of each panel. (*E*) Expression of *CCL5* mRNA in *BECN1*^−^ B16-F10 cells (*Upper*). The expression of Beclin1 protein was assessed by Western blot. Actin was used as loading control. \*\**P* \< 0.01 (two-tailed Student\'s *t* test). (*F*) Expression of *CCL5* in B16-F10 cells transfected with *ATG5* siRNA (ATG5-) and in cells treated with chloroquine (CQ) or transfected with *p62/SQSTM1* siRNA (p62-) (*Upper*). The expression of ATG5, LC3-I and -II, as well as p62/SQSTM1 proteins was assessed by Western blot. Actin and GAPDH were used as loading controls. Results are reported as a fold-change (FC) compared with Ctrl. Data represent the average ± SEM of three independent experiments. \*\**P* \< 0.01 (two-tailed Student's *t* test).](pnas.1703921114fig02){#fig02}

The impact of targeting *BECN1* on the expression of CCL5 was further assessed in human melanoma cell lines displaying low levels of CCL5. Indeed, according the expression value (log~2~) of CCL5 in 62 human melanoma cell lines reported by the Cancer Cell Line Encyclopedia (<https://software.broadinstitute.org/morpheus/>), we selected three human melanoma cell lines---A375, IPC298, and MelJuso---displaying a relatively low expression level of CCL5 mRNA ([Fig. S2](#sfig02){ref-type="fig"}). [Fig. 2*C*](#fig02){ref-type="fig"} shows that, similarly to B16-F10 cells, targeting *BECN1* in A375, IPC298, and MelJuso human melanoma cell lines induced a significant increase in the secretion of CCL5, indicating that the up-regulation of CCL5 resulting from targeting *BECN1* is not restricted to B16-F10 but can also be observed in other human melanoma cell lines.

![Relative expression level of CCL5 in melanoma cell lines. Relative expression level of mRNA (log) in 162 skin cancer cell lines reported according to the Cancer Cell Line Encyclopedia (CCLE; <https://software.broadinstitute.org/morpheus/>). Black arrowheads indicate melanoma cell line used.](pnas.1703921114sfig02){#sfig02}

To further determine the involvement of CCL5 in the migration of NK cells, we tracked the migration of human NK cells toward a CCL5 gradient, using ibidi slides and a cell IQ platform. [Fig. 2*D*](#fig02){ref-type="fig"} shows that, in the absence of CCL5, NK cells migrate randomly (50% of cells to the upper and 50% to the lower compartments) in short-distance migration trajectories. Interestingly, the presence of a CCL5 gradient in the upper compartment induced directional long-distance migration of 80% of the NK cells toward that compartment. These results strongly suggest that CCL5 is a key determinant for the migration of NK cells.

A growing body of evidence has revealed that, in addition to its role in autophagy, *BECN1* has several nonautophagic functions ([@r28]). We therefore investigated whether targeting other autophagy genes could also induce CCL5. We first determined whether CCL5 is regulated at mRNA level. Our results ([Fig. 2*E*](#fig02){ref-type="fig"}) show that, in *BECN1*^−^ tumor cells, CCL5 is up-regulated at the transcription level as a significant increase in the mRNA of CCL5 was observed in BECN1^−^ B16-F10 cells. Next, to determine to what extent the autophagy process is involved in the regulation of *CCL5*, we evaluated the impact of targeting other autophagy genes on the expression of *CCL5*. We show that, similarly to *BECN1*, targeting *ATG5* or *p62*/*SQSTM1* or treating cells with chloroquine, an autophagy inhibitor ([Fig. 2*F*](#fig02){ref-type="fig"}), resulted in a significant increase in the expression of *CCL5* mRNA in B16-F10 melanoma cells. Taken together, these data provide clear evidence that---not only *BECN1* but also the autophagy process---are involved in the regulation of *CCL5*.

Targeting *BECN1* Induces the Expression of *CCL5* Transcription Factor c-Jun. {#s4}
------------------------------------------------------------------------------

To gain more insight into the molecular mechanisms involved in the up-regulation of CCL5 mRNA in BECN1^−^ B16-F10 cells, we focused our interest on the major transcription factor involved in the regulation of the CCL5 transcript. Indeed, the promoter region of mouse and human CCL5 contains several binding sites for well-defined transcription factors ([@r29]), including AP-1. We first assessed whether c-Jun binds to the CCL5 promoter in B16-F10 cells. We performed in silico identification of consensus (5′-TGA\[C/G\]TCA-3′) ([@r30]) and nonconsensus (5′-TGACTgA-3′ or 5′-TGACTCc-3′) ([@r31]) motifs for the Jun/Fos AP-1 binding site on the mouse CCL5 promoter. The promoter containing fragment has been defined using the Eukaryotic Promoter Database (Swiss Institute of Bioinformatics) from −8,000 to +100 bp relative to the transcription start site (TSS) of the mouse CCL5 gene (RefSeq NM_013653.3). Fuzznuc EMBOSS searches for patterns in nucleotide sequences software identified two consensus and two nonconsensus AP-1 binding sites, highlighted in red and green, respectively, on the sequence (shown in [Fig. S3*A*](#sfig03){ref-type="fig"}). The positions of the consensus motifs were −7,668 and −5,489 and those of the nonconsensus motifs were −7,636 and −5,129 ([Fig. S3*B*](#sfig03){ref-type="fig"}). ChIP was performed on CCL5-overexpressing BECN1^−^ B16-F10 cells using anti--c-Jun ChIP grade antibody. Our results, depicted in [Fig. S3*C*](#sfig03){ref-type="fig"}, show that c-Jun strongly binds to the nonconsensus 5′-TGACTgA-3′ motif containing region C of the CCL5 promoter, indicating that CCL5 is a direct c-Jun target gene in BECN1^−^ B16-F10 cells.

![c-Jun binds directly to the AP-1 nonconsensus motif in the CCL5 promoter. (*A*) The sequence from −8,000 to +100 bp relative to TSS containing CCL5 promoter defined by the Eukaryotic Promoter Database (Swiss Institute of Bioinformatics). Consensus and nonconsensus AP-1 binding motifs are highlighted in red and green, respectively. Sequences flanking AP-1 motifs (regions A, B, and C) are highlighted in gray. The TSS and ATG positions are indicated. (*B*) Schematic representation of AP-1 binding motifs in CCL5 promoter containing region. The position of each motif is reported. (*C*) ChIP was performed on BECN1^−^ B16-F10 cells using control isotype (IgG) or anti--c-Jun antibody followed by SYBR Green reverse-transcriptase qPCR using appropriate primers for regions A, B, and C. Reverse-transcription qPCR signals were normalized to the control. Statistically significant differences (indicated by asterisks) between control and c-Jun conditions are shown (\**P* \< 0.05). Two separate experiments (in triplicates) with the same results were performed. Error bars indicate SD.](pnas.1703921114sfig03){#sfig03}

We next investigated the expression and the activation of c-Jun, the AP-1 founding member ([@r32]). It is known that c-Jun is transactivated by phosphorylation at the N terminal Ser-63 and Ser-73 residues ([@r33], [@r34]). Our results showed that the total and the phosphorylated level of c-Jun at both Ser-63 and Ser-73 residues were higher in BECN1^−^ compared with control B16-F10 cells ([Fig. 3*A*](#fig03){ref-type="fig"}, *Left*). An increase in the phosphorylation of c-Jun was also observed in BECN1^−^ tumor extracts ([Fig. 3*A*](#fig03){ref-type="fig"}, *Right*).

![Targeting autophagy induces the up-regulation of *CCL5* mRNA by increasing the phosphorylation of c-Jun. (*A*, *Left*) Expression of Beclin1, total c-Jun, phosphorylated c-Jun on serine 63 (pS63), and serine 73 (pS73) proteins in cell extracts from Ctrl and BECN1^−^ B16-F10 cells. Actin was used as loading control. (*Right*) Expression of Beclin1, phosphorylated c-Jun on serine 63 (pS63), and serine 73 (pS73) proteins in three regions (\#1, \#2, \#3) of Ctrl and BECN1^−^ B16-F10 tumor extracts. Actin was used as loading control. (*B*) Expression of Beclin1, total and phosphorylated SEK/MKK4 on Ser-80, Thr-261, and Ser-257, and phosphorylated JNK on Thr-185/Tyr-183 in Ctrl and BECN1^−^ B16-F10 melanoma cells. (*C*, *Upper*) Expression of Beclin1, phosphorylated JNK on Thr-185/Tyr-183, and phosphorylated c-Jun on serine 63 (pS63) and serine 73 (pS73) proteins in Ctrl and BECN1^−^ cells untreated (−) or treated (+) with JNK inhibitor SP600125. Actin was used as loading control. (*Lower*) The expression of *CCL5* mRNA in cells described in the *Upper* panel. Data are reported as fold-change (FC) compared with the Ctrl. \**P* \< 0.05 (two-tailed Student\'s *t* test). (*D*, *Upper*) BECN1^−^ B16-F10 melanoma cells were transfected with control (Ctrl) or JNK1/2 (JNK) siRNA. The expressions of JNK, Ser-63 (pS63), and Ser-73 (pS73) phosphorylated c-Jun were assessed 72 h after transfection. Vinculin was used as loading control. (*Lower*) The expression of CCL5 mRNA by real-time RT-PCR in cells described in *A*. Data represent the average ± SD of three independent experiments. \*\*\**P* \< 0.005 (two tailed Student's *t* test). (*E*) PP2A phosphatase activity assay in Ctrl and BECN1^−^ B16-F10 tumor cells. Data reported as picomoles of free phosphate released following incubation of PP2Ac immunoprecipitated from each cell with Threonine phosphopeptide. The result shown is the average ± SEM of five independent experiments performed in duplicate. \**P* \< 0.05 (two-tailed Student's *t* test). (*F*, *Left*) Expression of PP2A subunit A, total and phosphorylated c-Jun on serine 63 (pS63) and serine 73 (pS73) and total and phosphorylated JNK on Thr-185/Tyr-183 proteins in Ctrl B16-F10 cells untransfected (−) or transfected with PP2A siRNA targeting A subunit. Actin was used as loading control. (*Right*) Expression of *CCL5* mRNA in the cells described in the *Left* panel. Data are reported as fold-change (FC) compared with the Ctrl. Results represent the average ± SEM of three independent experiments. \*\**P* \< 0.01 (two-tailed Student's *t* test). (*G*, *Upper*) Expression of phosphorylated PP2A on Tyr-307 PP2A and phosphorylated c-Jun on serine 63 (pS63) in Ctrl B16-F10 cells untreated (−) or treated (+) with okadaic acid (OA). (*Lower*) Quantification of CCL5 secreted by cells described in the *Upper* panel as determined by ELISA.](pnas.1703921114fig03){#fig03}

c-Jun phosphorylation is mediated by the upstream kinase JNK, which in turn is exclusively phosphorylated by MKK4 kinase ([@r35]). While no difference was observed in the total expression and the phosphorylation levels of MKK4, a significant increase in the phosphorylation of JNK at Thr-183 and Tyr-185 was detected in BECN1^−^ compared with Ctrl cells ([Fig. 3*B*](#fig03){ref-type="fig"}), suggesting that the increased phosphorylation level of c-Jun in BECN1^−^ cells is most likely related to an increased JNK activity. This assumption was further supported by our data showing that pharmacological ([Fig. 3*C*](#fig03){ref-type="fig"}, *Upper*) and genetic ([Fig. 3*D*](#fig03){ref-type="fig"}, *Upper*) inhibition of JNK completely suppressed, as expected, the phosphorylation of c-Jun at Ser-63 and Ser-73 residues and, more interestingly, led to a significant down-regulation of *CCL5* mRNA in *BECN1*^−^ tumor cells ([Fig. 3 *C* and *D*](#fig03){ref-type="fig"}, *Lower*).

It has long been postulated that the regulation of protein phosphorylation is partially balanced by the activity of kinases and phosphatases. The serine/threonine phosphatase, PP2A, has been described to be involved in the regulation of JNK phosphorylation and subsequently in that of its downstream protein c-Jun ([@r36]). In accordance with this, we assessed PP2A activity in Ctrl and BECN1^−^ B16-F10 cells to determine whether the increased levels of phosphorylated JNK and phosphorylated c-Jun are related to a defect in PP2A activity. The results ([Fig. 3*E*](#fig03){ref-type="fig"}) revealed that PP2A activity was significantly lower in BECN1^−^ compared with Ctrl B16-F10 cells, suggesting that the increased levels of phosphorylated JNK and phosphorylated c-Jun resulted from a decrease in the phosphatase activity of PP2A. This was further supported by our data showing that targeting PP2A subunit A genetically by siRNA in control cells increased the phosphorylation of both JNK and c-Jun ([Fig. 3*F*](#fig03){ref-type="fig"}, *Left*), and subsequently increased the expression of CCL5 ([Fig. 3*F*](#fig03){ref-type="fig"}, *Right*). Similarly, treatment of control cells with PP2A inhibitor okadaic acid inhibited its catalytic activity by increasing the phosphorylation at Tyr-307 ([Fig. 3*G*](#fig03){ref-type="fig"}, *Upper*). Such inhibition enhanced the phosphorylation of c-Jun at Ser-63 and increased the expression of CCL5 ([Fig. 3*G*](#fig03){ref-type="fig"}, *Lower*). Overall, these results provide a mechanistic clue on how targeting autophagy increases the expression of CCL5 by enhancing the phosphorylation of c-Jun.

Targeting CCL5 in *BECN1*^−^ Tumors Significantly Reduces the Infiltration of NK Cells into the Tumor Bed and Prevents Tumor Regression. {#s5}
----------------------------------------------------------------------------------------------------------------------------------------

We next investigated the impact of silencing CCL5 on the tumor growth and on the infiltration of NK cells in BECN1^−^ B16-F10 tumors. We generated B16-F10 cells defective for both *BECN1* and *CCL5* (*BECN1*^−^/*CCL5*^−^) and characterized them in terms of *BECN1* expression and CCL5 secretion. Our results, shown in [Fig. 4*A*](#fig04){ref-type="fig"}, demonstrate a significant inhibition of the secretion of CCL5 in BECN1^−^/CCL5^−^ cells. [Fig. 4*B*](#fig04){ref-type="fig"} clearly shows that the reduction of tumor growth, seen in *BECN1*^−^ tumors ([Fig. 4*B*](#fig04){ref-type="fig"}, red curve) compared with controls ([Fig. 4*B*](#fig04){ref-type="fig"}, black curve), was no longer observed when *CCL5* was silenced ([Fig. 4*B*](#fig04){ref-type="fig"}, gray curve). Interestingly, immunohistochemistry staining demonstrated that targeting *CCL5* in BECN1^−^ tumors dramatically prevented the infiltration of NK cells into the tumor bed ([Fig. 4*C*](#fig04){ref-type="fig"}). The quantification of the percentage of NK cells infiltrating the tumors is shown in [Fig. 4*D*](#fig04){ref-type="fig"}. These data provide additional support that the recruitment of NK cells into BECN1^−^ B16-F10 tumors is driven by CCL5. Because the JNK/c-Jun pathway has been identified in vitro as the major transcription factor involved in the up-regulation of CCL5 in BECN1^−^ tumor cells, our results showed that genetic targeting of JNK/c-Jun pathway ([Fig. 4*E*](#fig04){ref-type="fig"}) resulted in a dramatic decrease in CCL5 expression ([Fig. 4*F*](#fig04){ref-type="fig"}) and an increase in BECN1^−^ tumor volume ([Fig. 4*G*](#fig04){ref-type="fig"}) and weight ([Fig. 4*H*](#fig04){ref-type="fig"}). Interestingly, there was a significant decrease in both the expression of tumoral CCL5 ([Fig. 4*I*](#fig04){ref-type="fig"}) and the infiltration of NK cells into the tumor bed ([Fig. 4*J*](#fig04){ref-type="fig"} and [Fig. S4](#sfig04){ref-type="fig"}). Overall, our data provide evidence that JNK/c-Jun/CCL5 pathway regulates the recruitment of NK cells into BECN1^−^ tumors.

![CCL5 is the major chemokine involved in the infiltration of NK cells into BECN1^−^ B16-F10 tumor. (*A*, *Upper*) Expression of Beclin1 protein in Ctrl, BECN1^−^, and BECN1^−^/CCL5^−^ cells. Actin was used as loading control. (*Lower*) Quantification of CCL5 secreted into the supernatants of the cells described in the *Upper* panel. Data represent the average ± SEM of three independent experiments. \*\*\**P* \< 0.001 (two-tailed *t* test). (*B*) Tumor cells described above were engrafted subcutaneously in C57BL/6 mice (*n* = 8 per group). Tumor volume was measured at the indicated days and the average ± SEM was reported. \**P* \< 0.05; \*\**P* \< 0.01 (two-tailed Student's *t* test). (*C*) Immunohistochemical staining of NK cells (*Upper*) or CCL5 (*Lower*) performed on indicated tumor sections using anti--Asialo-GM1 and CCL5 antibodies, respectively. (Scale bars, 200 µm.) (*D*) Quantification of NK cells infiltrating Ctrl, BECN1^−^ and BECN1^−^/CCL5^−^ tumors reported as a percentage (%) of the total number of cells for each tumor. Data represent the average ± SEM of two sections from two independent tumors. \**P* \< 0.05; \*\**P* \< 0.01; ns, not-significant (two-tailed Student's *t* test). (*E*) BECN1^−^ B16-F10 melanoma cells were infected with control (Ctrl) or JNK1/2 (JNK) shRNA. The expressions of JNK, c-Jun, and Beclin1 were assessed. Vinculin was used as loading control. The panel corresponding to the expression of Beclin1 was generated from the same blot but consolidated from noncontiguous loading. (*F*) The expression of CCL5 mRNA by real-time RT-PCR in cells described in *E*. Data represent the average ± SEM of three independent experiments. \*\*\**P* \< 0.005 (two tailed Student's *t* test). (*G*) BECN1^−^ and BECN1^−^/JNK^−^ tumor cells described in *E* were engrafted subcutaneously in C57BL/6 mice (*n* = 5 or 6 per group). Tumor volume was measured at the indicated days and the average ± SEM was reported. \**P* \< 0.05; \*\**P* \< 0.01 (two-tailed Student's *t* test). (*H*) The weight of BECN1^−^ and BECN1^−^/JNK^−^ tumors described in *G* at day 18. \**P* \< 0.05 (two-tailed Student's *t* test). (*I*) Immunohistochemical staining of CCL5 performed on BECN1^−^ and BECN1^−^/JNK^−^ tumor sections using anti-CCL5 antibody. (Scale bars, 100 µm.) (*J*) Quantification of NK cells infiltrating BECN1^−^ and BECN1^−^/JNK^−^ tumors reported as a percentage (%) of the total number of cells for each tumor. Data represent the average ± SEM of two sections from one independent tumor. \**P* \< 0.05 (two-tailed Student's *t* test).](pnas.1703921114fig04){#fig04}

![The gating strategy used to quantify NK cell-infiltrating tumors.](pnas.1703921114sfig04){#sfig04}

The Expression of CCL5 Positively Correlates with Expression of the NK Cell Marker NKp46 and Predicts Improvement of Melanoma Patients' Survival. {#s6}
-------------------------------------------------------------------------------------------------------------------------------------------------

We next investigated whether a positive correlation could be found between the expression of CCL5 and the infiltration of NK cells in melanoma patients. Sections of melanoma tumor biopsies were first stained with CCL5 and assigned, according to the expression level of CCL5, as no, low, moderate, high, and very-high CCL5 staining. These tumors were further stained with the NK cell marker NKp46. Our results reveal a striking positive correlation between the expression levels of CCL5 and NKp46 ([Fig. 5*A*](#fig05){ref-type="fig"}). Our data were further confirmed by quantitative real-time PCR performed using mRNA isolated from a panel of 22 melanoma biopsies ([Fig. 5*B*](#fig05){ref-type="fig"}). To extend our study to an even larger cohort of melanoma patients, we used data from 471 skin cutaneous melanomas described in the TCGA database. As expected, a strong positive correlation was also observed between the expression of *CCL5* and the expression of the NKp46 encoding gene *NCR1* ([Fig. 5*C*](#fig05){ref-type="fig"}). Taken together, these results highly suggest that melanoma tumors expressing high levels of CCL5 are strongly infiltrated by NK cells.

![CCL5 overexpression is correlated with the increase of NKp46 and the improvement of melanoma patients' survival. (*A*) Twelve FFPE melanoma biopsy sections were stained with CCL5 (*Left*) or NKp46 (*Right*) antibodies and immunohistochemical analysis showed that tumor sections strongly positive for CCL5, also had an abundant number of NK cells. Five representative sections (P1 to P5) are reported. (Scale bars, 100 μm.) (*B*) RNA extracted from 22 melanoma biopsies were assessed for the expression of CCL5 and NKp46 encoding *NCR1* gene. The Spearman test showed a significant and positive correlation between the expression of *CCL5* and *NCR1*. (*C*) A similar Spearman correlation test was set up using RNA-Seq data of 471 skin cutaneous melanomas described in the TCGA database. A positive correlation was found between the expression of *CCL5* and *NCR1*. The expression of each gene was reported as RNA-Seq V2RSEM (RNA-Seq expression estimation by expectation-maximization). (*D*) Kaplan--Meier survival plot of skin cutaneous melanoma (SKCM) patients generated using OncoLnc resource. TCGA data of 458 melanoma patients were assigned into low or high groups according to the expression level of *CCL5* reported as RNASeq values. Patients having a *CCL5* expression level ranging from 7.92 to 588 were considered as low (blue curve) and those having a *CCL5* expression level ranging from 588 to 32,675 were considered as high (red curve). Statistically significant difference is indicated by *P* value.](pnas.1703921114fig05){#fig05}

We next assessed the impact of *CCL5* level on the survival of 458 melanoma patients using the recently described OncoLnc resource ([www.oncolnc.org](http://www.oncolnc.org/)). This resource links RNAseq data of particular genes with patients' survival using clinical data from The Cancer Genome Atlas (TCGA) ([@r37]). Based on RNAseq data, the median log expression level of *CCL5* in melanoma patients was 588.44 (reported as a "log"). According to the expression level of CCL5, the 458 melanoma samples were assigned into low and high CCL5-expressing groups, each of them containing 229 samples. The expression of CCL5 in the low and high groups ranged from 7.92 to 588 and from 588 to 32,675, respectively. The Kaplan--Meier survival plot reported in [Fig. 5*D*](#fig05){ref-type="fig"} depicts that melanoma patients with an elevated expression level of *CCL5* had a significant longer survival. Taken together, these data strongly suggest that the improvement of the survival of melanoma patients displaying a high level of *CCL5* is most likely due to an increase in the infiltration of NK cells into the tumors.

Discussion {#s7}
==========

The role of NK cells in the improvement of immune responses to cancer has been extensively investigated during the past few decades, and several NK cell-based immunotherapies have been proposed and are used in the clinic ([@r38]).

CCL5, also known as RANTES, is a small protein that belongs to a large family of cytokines and displays chemotaxis activity, as it is involved in inducing the migration of several leukocytes into inflammation sites ([@r39]). CCL5 is secreted by a wide variety of cells, including T cells ([@r40]), NKs ([@r27]), and some tumor cells ([@r41]). CCL5 interacts with different receptors including C-C chemokine receptor types 1, 3, and 5 (CCR1, CCR3, and CCR5) ([@r42]). Controversial data exist about the role of CCL5 in the tumor microenvironment. While some reports highlight the role of CCL5 in promoting breast cancer metastasis ([@r43]), others refer the importance of CCL5 in T cell recruitment into melanomas ([@r26]). It seems that the pro- or the antioncogenic roles of CCL5 depends on the tumor type, the nature of the cells secreting CCL5, and the different interactions within the tumor microenvironment. Although the role of CCL5 in the recruitment of NK cells in inflammation and allergic diseases has been widely studied, no data are available so far about its role in the recruitment of NK cells into the tumor microenvironment. In line with our previous work, which showed that targeting autophagy improves the NK-mediated antitumor immune response ([@r17]), we show here that inhibiting autophagy increases the expression and the release of CCL5 by murine B16-F10 tumor cells both in vitro and in vivo, which subsequently led to a massive infiltration of NK cells into the tumor bed. Because the expression of CCL5 was also observed in ATG5-defective cells and after chloroquine treatment, we strongly believe that targeting the autophagy mechanism as a whole, rather than specifically targeting *BECN1*, results in the improvement of the NK-mediated antitumor immune responses by inducing NK cell-homing into tumors.

It has been previously reported that CCL5 can increase the cytotoxicity of CD56^+^ human NK cells ([@r44]). Other studies also showed that CCL5 promotes the release of cytotoxic granules by human NK cells ([@r45][@r46]--[@r47]). We therefore asked whether an elevated level of CCL5 could enhance the cytolytic activity of NK cell-infiltrating tumors. We strongly believe that CCL5 released by *BECN1*^−^ tumor cells has no impact on the activation status of NK cells as, when reported to the total number of NK cells, no differences in the expression of NK cell-activation markers CD69 and GzmB were observed in NK cell-infiltrating control or *BECN1*^−^ tumors.

Another important question is to determine whether CCL5 is the only factor involved in the recruitment of NK cells. Indeed, in addition to CCL5, our cytokine array revealed that CXCL10 was found to be up-regulated in *BECN1*^−^ tumor cells, although at a lower extent. Based on the fact that CXCL10 has also been described to induce the migration of NK cells ([@r27]), the involvement of CXCL10 in the homing of NK cells cannot be ruled out, and additional experiments need to be conducted to determine the relative contribution of CXCL10. Nevertheless, our data showed that targeting CCL5 was sufficient to significantly suppress the infiltration of NK cells and subsequently enhance the tumor growth in *BECN1*^−^ tumors, strongly suggesting that CCL5 is the major factor involved in the recruitment of NK cells to B16-F10 melanoma tumors.

CCL5 elicits its chemo-attracting activity by acting via CCR1, CCR3, and CCR5 ([@r48]). As such, the increased migration of NK cells toward a CCL5 gradient could be related to the increased expression of CCL5 receptors on the surface of NK cells infiltrating *BECN1*^−^ tumors. This possibility can be ruled out since no difference in the expression of CCR1, CCR3, and CCR5 was found on the surface of NK cells infiltrating both control and *BECN1*^−^ tumors ([Fig. S5](#sfig05){ref-type="fig"}). Interestingly, we even observed that *BECN1*^−^ B16-F10 cells isolated from tumors exhibited significantly lower levels of CCR1, CCR3, and CCR5 compared with controls ([Fig. S6](#sfig06){ref-type="fig"}). This implies that the autocrine CCL5 signaling, previously described to promote the invasion and migration of tumor cells ([@r49]), is attenuated in *BECN1*^−^ tumor cells, and that CCL5 released by tumor cells primarily acts via paracrine signaling to attract NKs to the tumor bed. However, how the CCL5 receptors are regulated in *BECN1*^−^ tumors remains, so far, an unresolved issue that needs to be further investigated.

![Percentage of CCL5 receptors expressed on NK cells infiltrated in Ctrl and BECN1^−^ B16-F10 tumors. NK cells infiltrating Ctrl and BECN1^−^ B16-F10 tumors were stained with NK1.1-, CCR1-, CCR3-, and CCR5-specific antibodies and subjected to flow cytometric analyses. NK1.1^+^/CD45^+^CD11b^−^CD19^−^ cells were gated and the percentage of CCR1^+^, CCR3^+^, and CCR5^+^ NK cells were determined. (*A*) Representative flow cytometry plots of NK1.1^+^CCR1^+^, NK1.1^+^CCR3^+^, and NK1.1^+^CCR5^+^ in Ctrl and BECN1^−^ B16-F10 tumors. Quadrant settings were based on the cells stained with FMO and then applied to the plots of cells stained with positive antibodies. (*B*) Percentage of CCR1^+^, CCR3^+^, and CCR5^+^ total NK cells infiltrating Ctrl and *BECN1*^−^ tumors. Not-significant differences were observed in CCR1, CCR3, and CCR5 between Ctrl and *BECN1*^−^ tumors.](pnas.1703921114sfig05){#sfig05}

![Percentage of CCL5 receptors expressed in Ctrl and BECN1^−^ B16-F10 tumors. Tumor cells from Ctrl and BECN1^−^ B16-F10 tumors were stained with CCR1-, CCR3-, and CCR5-specific antibodies and were subjected to flow cytometric analyses. CD45^−^ cells were gated and defined as tumor cells after which the percentage of CCR1^+^, CCR3^+^, and CCR5^+^ tumor cells were determined. (*A*) Representative flow cytometry plots of CD45^−^CCR1^+^; CD45^−^CCR3^+^, and CD45^−^CCR5^+^ in Ctrl and BECN1^−^ B16-F10 tumors. Quadrant settings were based on the cells stained with FMO and then applied to the plots of cells stained with positive antibodies. (*B*) Percentage of CCR1, CCR3, and CCR5 in total CD45^−^ cells from Ctrl and BECN1^−^ B16-F10 tumors. Data shows the significant differences in the percentage of CCR1, CCR3, and CCR5 between tumor cells from Ctrl and BECN1^−^ tumors. Results are the average ± SEM of four mice from each group. \**P* \< 0.05 (two-tailed Student's *t* test).](pnas.1703921114sfig06){#sfig06}

Mechanistically, we provide strong evidence that targeting BECN1 induces a dramatic phosphorylation of c-Jun at both Ser-63 and Ser-73 residues through PP2A-dependent increase of JNK phosphorylation. Therefore, our results predict that c-Jun is constitutively present in control cells in an inactive form and that targeting autophagy induces the phosphorylation of c-Jun at Ser-63 and Ser-73 residues located within its transactivation domain. Such phosphorylation serves to increase both its stability and transcriptional activity, as previously reported ([@r50], [@r51]).

The increase in the phosphorylation of JNK/c-Jun in BECN1^−^ cells seems to be tightly linked to the decreased activity of PP2A. Although the causal mechanisms underlying the decrease in PP2A activity in BECN1^−^ cells remains largely unknown, our data provide an important mechanistic clue on how CCL5 is transcriptionally regulated in *BECN1*^−^ tumor cells. A schematic representation of the mechanism underlying the expression of CCL5 in BECN1^−^ cells is reported in [Fig. 6](#fig06){ref-type="fig"}. In addition, we strongly believe that the increased-phosphorylation of c-Jun at Ser-63 residue is a consequence of targeting Beclin1 rather than the up-regulation of CCL5, as the level of phosphorylated c-Jun was not affected following CCL5 silencing in BECN1^−^ tumor cells ([Fig. S7](#sfig07){ref-type="fig"}).

![Schematic representation of the mechanism involved in the overexpression of CCL5 in BECN1^−^ tumor cells. Inhibition of autophagy by targeting *BECN1* decreases the catalytic phosphatase activity of PP2A by a mechanism that is not fully understood. The decreased PP2A activity leads to an increased phosphorylation of both JNK (p-JNK) and its downstream c-Jun at Ser-63 and Ser-73 (p-c-Jun Ser-63/-73). The activation of c-Jun by phosphorylation enhances the expression of CCL5 gene. CCL5 released by tumor cells attracts NK cells into the tumor bed leading to the decrease in tumor growth.](pnas.1703921114fig06){#fig06}

![The high phosphorylation level of c-Jun on Ser-63 in BECN1^−^ B16-F10 cells is not affected by silencing CCL5. Control and BECN1^−^ B16-F10 cells displaying a high level of Ser-63 phosphorylated c-Jun were transfected with shRNA targeting CCL5. The expression of Beclin1 and Ser-63 (pS63) c-Jun was assessed by Western blot. Actin was used as a loading control.](pnas.1703921114sfig07){#sfig07}

It is now well established that tumor infiltration by NK cells represents a positive prognostic marker in different cancers, including colorectal ([@r7]), gastric ([@r52]), and lung carcinomas ([@r53]). It has been suggested that low NK cell numbers in tumors are likely due to their inefficient homing into the tumor bed, which could be overcome by cytokine-mediated activation ([@r2]). Furthermore, convincing evidence for a beneficial role of NK cells in the control of tumor growth was provided from clinical studies of leukemia patients who received alloreactive NK cells in the course of allogenic hematopoietic stem cell transplantation ([@r2]). Using a small cohort of melanoma tumor biopsies, we show here a striking correlation between the expression of CCL5 and NK cell marker NKp46 at the protein and mRNA levels. As tumoral CCL5 has been described to recruit T cells ([@r54]) and macrophages ([@r55]) into the tumor bed as well, we cannot exclude that melanoma tumors expressing a high level of CCL5 are not only highly infiltrated by NK cells but also by T cells and macrophages. Furthermore, it should be noted that the CCL5 staining detected in melanoma biopsies may not be only produced by tumor cells, since other cells in the tumor microenvironment---such as T cells---can also secrete CCL5, as previously reported ([@r56], [@r57]). Nevertheless, the positive correlation between CCL5 and NK cells was further confirmed using more than 400 melanoma patients from the TCGA database. Consistent with the fact that CCL5 induces the homing of NK cells into the tumor bed, it stands to reason that CCL5 overexpression impacts on the survival of melanoma patients. Accordingly, we show that the long-term survival of melanoma patients overexpressing CCL5 was significantly improved.

It is now well accepted that NK cells are capable of driving potent antitumor responses ([@r58]). However, tumor cells often compromise the antitumor immunity by inducing an immunosuppressive microenvironment ([@r59]). Our data reported here reveal the impact of targeting autophagy in tumor cells on the release of chemokine involved in the infiltration of NK cells. Although much remains to be learned mechanistically, this study provides a cutting-edge approach on how to switch the immunosuppressive tumor microenvironment to an immunosupportive one, allowing for the redirection of NK cells to the tumor bed. One issue of great interest that remains to be addressed is to investigate the impact of targeting autophagy on the immune landscape of tumors and on the infiltration of other populations of immune cells into the tumor bed. Nevertheless, it is our belief that the knowledge generated from this study will pave the way to fully exploit NK cells' antitumor properties in clinical settings.

Materials and Methods {#s8}
=====================

Immunoblot Assays. {#s9}
------------------

Cell lysates were prepared using RIPA lysis buffer (20-188; Millipore) supplemented with a protease inhibitor mixture (11873580001; Prophac) and phosphatase inhibitor mixture 2 and 3 (P5726-5ML and P0044-5ML; Sigma). Protein concentration was determined using Bio-Rad protein assay dye reagent (500-0006; Bio-Rad). Equal amounts of proteins were loaded on SDS/PAGE gel, transferred to nitrocellulose membranes, and blocked with either 5% of milk or 5% of BSA according to the manufacturer's instructions for each antibody. The following primary antibodies were used: Beclin1 (3738; Cell Signaling), c-Jun (9165S; Cell Signaling), phospho c-Jun S63 (9261S; Cell Signaling), phospho c-Jun S73 (3270S; Cell Signaling), LC3II (2775S; Cell Signaling), ATG5 (MBL 153-3; MBL), GAPDH (5174S; Cell Signaling), SAPK/JNK (9552S; Cell Signaling), phospho SAPK/JNK (Thr183/Tyr185) (9251S; Sell Signaling), PP2A subunit A (2041; Cell Signaling), phospho PP2A tyr307 (sc-271903; Santa Cruz), SEK1/MKK4 (9152S; Cell Signaling), phospho SEK1/MKK4 S257 (4514P; Cell Signaling), phospho SEK1/MKK4 S80 (9155S; Cell Signaling), phospho SEK1/MKK4 Thr261 (9151S; Cell Signaling), and actin (A5441; Sigma Aldrich). Blots were then incubated with horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories). Proteins were detected using enhanced chemiluminescence ECL (GE Healthcare).

RNA Extraction and Reverse-Transcriptase PCR. {#s10}
---------------------------------------------

Total RNAs were extracted using the miRCURY RNA isolation kit (300110; Exiqon). RNA (1 µg) from each sample was reverse-transcribed using a reverse-transcription reaction mix (Eurogentec). The reverse transcription was performed at 48 °C for 30 min. The resulting cDNA was subjected to amplification by qPCR using power SYBR green PCR master mix (Life Technologies). The *RPL13* gene encoding Ribosomal Protein L13 was used as internal control. For mouse *RPL13*, the following primers were used: forward 5′-GGAGGGGCAGGTTCTGGTAT-3′ and reverse 5′-TGTTGATGCCTTCACAGCGT-3′. For mouse *CCL5*, the following primers were used: forward 5′-CTGCTGCTTTGCCTACCTCT-3′ and reverse 5′-CGAGTGACAAACACGACTGC-3′. RNAs from melanoma patients were provided by the Gustave Roussy Cancer Center, Villejuif, France. Briefly, RNAs from frozen melanoma were extracted using the Qiagen miRNEasy kit (217004; Courtaboeuf) and those from formalin-fixed paraffin-embedded (FFPE) were extracted using the Qiagen RNeasy FFPE kit (73504; Qiagen). RNAs were quantified by Nanodrop and their quality was verified by Bioanalyzer. The reverse-transcription qPCR was performed by AnyGenes Company (Tenon Hospital, Paris). Information related to the primers used amplification is the following. *PPIA* and *ACTB* genes encoding Peptidylprolyl isomerase A and actin β, respectively, were used as internal loading controls; for NKp46 encoding *NCR1* gene, the forward primer is localized in exon 4 and the reverse primer is localized at the junction of exons 4 and 5; for *CCL5*, the forward and reverse primers are localized in exon 1 and 2, respectively; for *PPIA*, the forward and reverse primers are localized in exon 1 and 2, respectively; and for *ACTB*, the forward and reverse primers are localized in exon 6.

Cytokine Array and ELISA Measurement of Mouse and Human CCL5. {#s11}
-------------------------------------------------------------

The profiling of different cytokines and chemokines was performed by Mouse cytokine array, and panel A (R&D systems) according to the manufacturer's instructions using serum-free supernatant harvested from equal number of cells. The signal intensities of the spots were quantified by ImageJ. CCL5 secretion by cells was quantified using the CCL5/RANTES Quantikine Elisa kit (R&D Systems) according to the manufacturer's instructions. The sensitivity of ELISA kits was 2.0 pg/mL for mouse CCL5 and 5.0 pg/mL for human CCL5.

In Vivo Tumor Growth and Flow Cytometry Analysis. {#s12}
-------------------------------------------------

Nine-week-old C57BL/6 mice were engrafted subcutaneously with B16F10 melanoma cells (2.3 × 10^5^ cells per mouse). Tumor growth was measured using a caliper every other day starting from day 11. Tumor volume was calculated as follows: volume (cm^3^) = 3.14159/6 × (width × length × height). B16-F10 tumor-bearing C57BL/6 mice were killed at day 21. The mouse experiments were performed according to the Luxembourg Institute of Health\'s instructions and guidelines and approved by the Luxembourg Institute of Health Ethical Committee. For flow cytometry analysis, cells were dissociated from tumors in DMEM complete medium, and centrifuged for 10 min at 4 °C. Red blood cells were lysed using ACK lysing buffer (10-548E; Lonza). Cells were counted and Fc-receptors were blocked with CD16/CD32 for 30 min before staining with appropriate antibodies. The following antibodies were used: BV421 anti-mouse NK1.1 (108731; Biolegend), Al700 anti-mouse CD19 (115528; Biolegend), APC-R700 rat anti-mouse CD11b (564985; BD Horizon), BUV395 rat anti-mouse CD45 (564279; BD Horizon), BV605 Hamster anti-mouse CD69 (563290; BD Horizon), Pacific blue anti-human/mouse GzmB (515407; Biolegend) and live/dead near IR (L10119; Life Technologies). CD45^+^/CD11b^−^/CD19^−^ cells were gated to determine the percentage of NK1.1^+^; NK1.1^+^GzmB^+^, and NK1.1^+^CD69^+^.

Immunohistochemistry Staining. {#s13}
------------------------------

FFPE tumor sections (5 µm) from B16-F10 tumors were used to determine the expression of NK and CCL5/RANTES by immunohistochemistry using rabbit anti-Asialo GM1 polyclonal antibody (986-10001; Wako Chemicals) and CCL5/RANTES antibody (NBP1-19769; Novus Biologicals) respectively. The staining was performed at the Laboratory of Experimental Pathology, Gustave Roussy Cancer Center, Villejuif, France. Stained sections were scanned with the Leica Aperio AT2 scanner and the number of NK^+^ and CCL5^+^ cells were quantified by HistoWiz Company using HALO software from Indica laboratories. FFPE sections from melanoma patients were assessed for the expression of CCL5 and NKp46 using NBP1-19769 and NBP2-11820 antibodies (Novus Biological), respectively. Stained sections were scanned with Leica Aperio AT2 by HistoWiz.

Cell Culture and Treatments. {#s14}
----------------------------

B16-F10 cells from ATCC were maintained in DMEM supplied with 10% of FBS and 1% of penicillin/streptomycin. IPC298, MelJuso and A375 cells were provided by S.K. and were maintained in RPMI medium supplied with 10% of FBS and 1% of penicillin/streptomycin. B16-F10 cells were treated with 60 µM of chloroquine during 4 h or with 20 µM of SP600125 overnight and washed before harvesting RNAs and proteins.

PP2A in Vitro Protein Phosphatase Assay. {#s15}
----------------------------------------

A PP2A immunoprecipitation phosphate assay kit (Millipore) was used to detect PP2A activity according to the manufacturer's instructions. Briefly, 200 μg of Ctrl and BECN1^−^ B16-F10 cells lysates were used to immunoprecipitate PP2A using anti-PP2Ac antibody. PP2A bound beads were washed with phosphatase assay buffer and phosphopeptide (KRpTIRR) in serine/threonine assay buffer (750 µM) was added and incubated 10 min at 30 °C. After centrifugation, 25 μL of the supernatant was transferred to a microplate and 100 μL of Green phosphate assay was added for 15 min. The relative absorbance was measured at 630 nm. The absorbance values were compared with negative controls containing no enzyme.

Generation of *BECN1*^−^ and *CCL5*^−^ B16-F10 Cell Line. {#s16}
---------------------------------------------------------

Scrambled and mouse *BECN1* short hairpin (shRNA) lentiviral particles were purchased from Santa Cruz Biotechnology. Cells were transduced in the presence of puromycin. Control and mouse CCL5 SureSilencing shRNA encoding plasmids were purchased from Qiagen. Transfected cells were maintained in the presence of hygromycin. Mouse JNK1 and JNK2 shRNA Lentiviral Particles were purchased from Santa Cruz Biotechnology.

In Vitro Chemotaxis Experiment. {#s17}
-------------------------------

The migration of NK92MI cells was evaluated in µ-Slide Chemotaxis^3D^ from ibidi according to the manufacturer's instructions. NK92MI cells (9 × 10^6^ cells/mL) cultured in serum-free medium in the absence or presence of 20 ng/mL of human recombinant CCL5/RANTES were transferred to the ibidi slide reservoirs. The time-lapse experiment was performed using Cell IQ platform during 48 h. One image was recorded every 15 min and the migration of NK92MI cells was analyzed by Tracking Tool PRO v2.0 software.

siRNA Transcfections. {#s18}
---------------------

Small interference RNAs (siRNA) were purchased from Qiagen. Cells were transfected using Lipofectamine RNAiMax reagent (13778-075; Life Technologies) in Opti-MEM reduced serum medium (31985070; Thermo Fisher Scientific). The following siRNAs against human Beclin1 were used: SI0005594 for IPC298 and A375, SI00055573 for MelJuso. siRNA against mouse ATG5 was SI02696806. siRNA against mouse p62 was SI02713445 (Qiagen). siRNA against mouse JNK1 was SI01300691. siRNA against JNK2 was SI01300803. Transfected cells were harvested for RNA and protein extractions.

In Vivo Experiments and Clinical Samples. {#s19}
-----------------------------------------

In vivo protocols were approved by the "Comité National d'Ethique de Recherche" Luxembourg, LHCE-2014-02. Clinical samples were collected from patients after having given their written informed consent in accordance with the declaration of Helsinki.

Statistical Analysis. {#s20}
---------------------

Statistically significant differences were evaluated using the unpaired two-tailed *t* test (SigmaPlot 12.5). A *P* value of less than 0.05 was considered statistically significant. Data were expressed as average ± SEM. The Spearman test was used to determine the correlation between the expression of *CCL5* and NKp46-encoding *NCR1* genes in melanoma patients. Melanoma patients' survival curves were generated by the OncoLnc tool (open access), which uses the Kaplan--Meier method for generating the curves and a log-rank test for calculating *P* values.

SI Materials and Methods {#si1}
========================

The following antibodies were used to perform staining on NK and tumor cells for flow cytometry analysis: PECD191 (FAB5986P-025; R&D), Percpcy5.5 CD193 (144515; Biolegend), AF488 CD195 (107008; Biolegend), BV421 anti-mouse NK1.1 (108731; Biolegend), Al700 anti-mouse CD19 (115528; Biolegend), APC-R700 Rat anti-mouse CD11b (564985; BD Horizon), and BUV395 Rat anti-mouse CD45 (564279; BD Horizon).
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